White Papers

2027-2028 GLP-1 Investment Guide

09/09/2026

As GLP-1 costs climb and pressure mounts to make a coverage decision, Omada's 2027-2028 GLP-1 Investment Guide offers benefit leaders new metrics for evaluating obesity care strategy, grounded in.

Beyond Stigma and Scripts: What the System Gets Wrong About Obesity Care

05/07/2026

In one of the largest surveys of its kind, Omada polled more than 3,000 people who have used GLP‑1s for weight loss, offering a timely view of how the GLP‑1 experience is evolving and where the.

Optimizing The Quantity and Quality of GLP-1 Weight Loss: Evidence from a 12-Week Comparative Study

04/10/2026

GLP‑1 medications have changed what’s possible for weight loss, but they also raise a critical question: what are people losing—fat, lean mass, or both? Omada’s Insights Lab conducted a 12‑week.

Webinars & Events

Beyond Point Solutions: Multi-Condition Support for Total Cost of Care

09/10/2026

Health plans are being asked to solve for total cost of care across a growing set of overlapping conditions — obesity, diabetes, hypertension, cholesterol, and multi-condition members at the.

The Story Between Visits: A New Lens on Cardiometabolic Care

06/03/2026

Cardiometabolic care is often discussed through the lens of prevalence, cost, and employer burden, but those data points often do not fully explain why many people struggle to sustain progress across.

NEBGH Cardiometabolic Health as a Business Imperative

03/16/2026

We’re thrilled to join the NEBGH Cardiometabolic Health as a Business Imperative Conference for the first time. This event brings together senior HR, benefits, and healthcare leaders for a strategic.

Keep Browsing

See All Posts
Become an Omada Insider
Sign Up